Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
ZPRÁVA ZE SYMPOZIA SPOTLIGHT ON PRECISION MEDICINE IN MYELOID MALIGNANCIES
27 ledna, 2021 8:38 pmV rámci satelitního sympozia společnosti Celgene „Spotlight on precision medicine in myeloid malignancies“ vystoupili E. Döhner a P. Montesinos, kteří se v rámci svých...
ONCE-WEEKLY VS TWICE-WEEKLY CARFILZOMIB DOSING PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE RANDOMIZED PHASE 3 STUDY A.R.R.O.W.
27 ledna, 2021 8:38 pmAuthor(s): Maria-Victoria Mateos, Philippe Moreau, James R. Berenson, et. al. Abstract: S849 Session topic: 14. Myeloma and other...
BUSULFAN + MELPHALAN WAS ASSOCIATED WITH A LONGER PFS COMPARED TO MELPHALAN ALONE IN HIGH-RISK MULTIPLE MYELOMA IN A RANDOMIZED PHASE 3 CLINICAL TRIAL
27 ledna, 2021 8:38 pmAuthor(s): Muzaffar Qazilbash, Qaiser Bashir, Peter Thall, et. al. Abstract: S124 Session topic: 23. Stem cell transplantation –...
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS
27 ledna, 2021 8:38 pmAuthor(s): Francesca Gay, Lorenzo De Paoli, Alessandra Larocca Abstract: PS1299 Session topic: 14. Myeloma and other monoclonal gammopathies...
CONSOLIDATION FOLLOWED BY MAINTENANCE VS MAINTENANCE ALONE IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE MULTIPLE MYELOMA: A RANDOMIZED PHASE 3 STUDY OF THE EUROPEAN MYELOMA NETWORK (EMN02/HO95 MM TRIAL)
27 ledna, 2021 8:38 pmAuthor(s): P Sonneveld, M Beksac, B vanderHolt, et. al. Abstract: S108 Session topic: 14. Myeloma and other monoclonal...
A TRIPLET BORTEZOMIB- AND IMMUNOMODULATOR-BASED THERAPY BEFORE AND AFTER DOUBLE ASCT IMPROVES OVERALL SURVIVAL OF NEWLY DIAGNOSED MM PATIENTS: FINAL ANALYSIS OF PHASE 3 GIMEMA-MMY-3006 STUDY
27 ledna, 2021 8:38 pmAuthor(s): Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, et. al. Abstract: S105 Session topic: 14. Myeloma and other...
MNOHOPOČETNÝ MYELÓM – Novinky z kongresu
27 ledna, 2021 8:38 pmMnohopočetný myelóm (MM) je veľmi heterogénne ochorenie, či už klinicky, biologicky alebo geneticky. Toto ochorenie však patrí v súčasnosti medzi hematologické...
PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND MULTILINEAGE DYSPLASIA WITH OR WITHOUT RING SIDEROBLASTS
27 ledna, 2021 8:38 pmAuthor(s): Abhishek Mangaonkar, Terra Lasho, Christy Finke, Naseema Gangat, et al. Abstract: PF501 Session topic: 10. Myelodysplastic syndromes...
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
27 ledna, 2021 8:38 pmAuthor(s): Paolo Strati, Guillermo Garcia-Manero, Tapan Kadia, Gautam Borthakur, et al. Abstract: PS1251 Session topic: 10. Myelodysplastic syndromes...
DESCRIPTION OF MUTATIONAL PROFILE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES AT THE TIME OF LEUKEMIC PROGRESSION
27 ledna, 2021 8:38 pmAuthor(s): Begoña Pedrote, Jose Francisco Falantes, Estrella Carrillo, Cristina Calderon-Cabrera, et al. Abstract: PF496 Session topic: 10. Myelodysplastic...